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p63Abstract Craniopharyngiomas (CPs) are rare epithelial tumors located mainly in the sellar/
parasellar region. CPs have been classiﬁed into histopathologically, genetically, clinically and
prognostically two distinctive subtypes: adamantinomatous and papillary variants.
Aim: To determine the immunohistochemical expression of b-catenin, EGFR, ErbB2, and p63 in
adamantinomatous and papillary CPs.
Materials and methods: b-Catenin, EGFR, ErbB2, and p63 immunostaining was performed on
parafﬁn embedded tissue sections of 25 CPs including 18 adamantinomatous craniopharyngioma
(ACP) and 7 cases of papillary craniopharyngiomas (PCPs).
Results: 17 cases (94%) of ACP exhibited strong nuclear/cytoplasmic expression of b-catenin. On
the contrary, all cases of PCP showed exclusively membranous expression (P value < 0.0001).
Regarding EGFR, 15 (83%) and 5 cases (71%) of APC and PCP respectively were positive. On
the other hand, only 3 cases (17%) of APC and none of PCP exhibited positivity for ErbB2. p63
over-expression was observed in 16 cases of ACP (89%) and 6 cases of PCP (86%). However,
140 G.E. Esheba, A.A. Hassanthe distribution of p63 staining was diffuse in ACP, while in PCP; the staining was mainly restricted
to the basal cell layer.
Conclusion: Nuclear accumulation of b-catenin is a diagnostic hallmark of the ACP and is very
helpful in the differential diagnosis between both ACP and PCP in the setting of small biopsies.
Moreover, the restricted nuclear b-catenin accumulation in the cohesive cell clusters within the
whorl-like areas supports that aberrant b-catenin expression may play a role in the morphogenesis
of ACP.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of National Cancer Institute,
Cairo University. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Craniopharyngioma is a benign, partly cystic epithelial tumor
of the sellar region presumably derived from Rathke pouch
epithelium and account for 1.2–4.6% of all intracranial tumors
[1–3]. They are the most common non-neuroepithelial intrac-
erebral neoplasm in children, accounting for 5–10% of
intracranial tumors [4].
Craniopharyngiomas are grade I tumors, according to the
World Health Organization classiﬁcation and although consid-
ered histologically benign, rare cases of malignant transforma-
tion (possibly triggered by previous irradiation) have been
reported [5,6].
Histologically, two main subtypes have been recognized,
the adamantinomatous and the papillary, however, transi-
tional or mixed forms have also been reported [7].
The adamantinomatous type is the most common, with a
bimodal age distribution, the ﬁrst peak in children aged 5–
15 years, while the second peak in adults aged 45–60 years. It
has similarity with the adamantinoma of the jaw and the cal-
cifying odontogenic cyst; it is thought to arise from squamous
cell rests of the craniopharyngeal duct, which is a canal that
connects the stomodeal ectoderm with Rathke’s pouch.
Conversely, papillary craniopharyngiomas have been
almost exclusively described in adults and result from meta-
plasia of the adenohypophyseal cells in the pituitary gland [3].
Craniopharyngioma may present with a variety of non-
speciﬁc manifestations including visual disturbances (more fre-
quently in adults than in children) and endocrine deﬁciencies
(more frequently in children). Cognitive impairment and per-
sonality changes are observed in about half of patients. Signs
of increased intracranial pressure are frequent, especially in
cases with compression or invasion of the third ventricle [8,9].
Despite their benign histological appearance, they often
show an unpredictable growth pattern. Currently, surgical
excision followed by external beam irradiation, in cases of
residual tumor, is the main treatment option. Intracystic irra-
diation or bleomycin, stereotactic radiosurgery, or radiother-
apy and systemic chemotherapy are alternative approaches
[10,11].
Recently, mutations of the glycogen synthase kinase 3b
(GSK3b) binding domain of b-catenin have been found in
adamantinomatous CP suggesting a potential role of the asso-
ciated Wnt/wingless signaling pathway during tumorigenesis
of ACP. Under physiological conditions, binding of Wnt to
a membrane receptor, such as frizzled, initiates an intracellular
signaling cascade and results in the inactivation of the cyto-
plasmic GSK3b complex including adenomatous polyposis
coli (APC), b-catenin, and axin. As a consequence,proteasomal b-catenin degradation is inhibited and b-catenin
molecules can translocate into the nucleus, where they interact
with members of the T cell factor (TCF) family of transcrip-
tion factors leading to activation of the expression of target
genes such as c-myc and cyclin D1 and stimulation of cellular
proliferation [12–16].
The epidermal growth factor receptor (EGFR) cascade has
been recognized to also play a role in Wnt signaling activation,
most probably due to a direct interaction between EGFR and
b-catenin. The EGFR is a 170-kDa receptor tyrosine kinase
(RTK), also referred to as HER1, ErbB1, mENA, and
PIG61. Aberrant EGFR signaling was identiﬁed in several
cancers such as non-small-cell lung cancer (NSCLC), colorec-
tal carcinoma, breast cancer, head and neck squamous carci-
noma, bladder cancer, and pancreatic cancer [17].
ErbB2 protein, encoded by the HER2neu gene, belongs to a
family of four homologous transmembrane receptors [epider-
mal growth factor receptor (EGFR)/ErbB1, ErbB2, ErbB3,
and ErbB4]. Overexpression of the ErbB2 protein has been
found in 20–25% of invasive ductal carcinomas and is associ-
ated with aggressive clinical behavior. ErbB2 expression was
also found in various human cancers such as ovarian, gastric,
esophageal, lung, and endometrial cancers. Therefore, ErbB2
has been the target for immunotherapy [18,19]. However, its
expression in craniopharyngioma has not been extensively
studied.
The aim of this study was to evaluate the immunohisto-
chemical expression of b-catenin, EGFR, ErbB2, and p63 in
adamantinomatous and papillary CPs.Materials and methods
25 Formalin-ﬁxed, parafﬁn-embedded tissue blocks containing
CP were obtained retrospectively from the archives of the
Departments of Pathology, Faculty of Medicine, Tanta and
Al Azhar Universities during the period between 2005 and
2013. The cases included 18 cases of ACP and 7 cases of pap-
illary craniopharyngioma.
This study was approved by the Ethics Committee of
Faculty of Medicine, Tanta University in accordance with
the principles of the Declaration of Helsinki.
Immunohistochemical analysis was done with the following
commercially available antibodies: b-catenin, EGFR, ErbB2,
and p63.
The characteristics of antibodies used for evaluation are
summarized in Table 1.
Four micrometer thick sections were cut from routine
parafﬁn embedded blocks then deparafﬁnized in xylene, and
Table 1 Characteristics of antibodies used for evaluation.
Antibody Clone Source Dilution
Anti-Human
b-catenin
M 3539 DOKO Cytomation,
Glostrup, Denmark
1:200
Anti-EGFR EP774Y Abcam, Cambridge, MA 1:250
Anti-ErbB2 NCL-L-CB
11
Novocastra
Laboratories, UK at
dilution
1:40
p63 4A4, Code
M 7247
DAKO, Carpinteria, CA 1:200
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with the Dako autostainer.
Scoring methods
For b-catenin expression, the cytoplasm/nuclear immunoreac-
tivity was evaluated separately from membranous immunore-
activity and the nuclear staining was scored as strong (3),
moderate (2), weak (1), or negative (0) [15].
Regarding EGFR staining, only staining of the tumor cell
membranes was considered to be speciﬁc. The staining pattern
of tumor cell membranes was further classiﬁed as incomplete
staining and complete staining. The following scoring
approach in the assessment of EGFR immunostaining was
used: score 0 = no staining or unspeciﬁc staining of tumor
cells; score 1 = weak (intensity) and incomplete staining (qual-
ity) of more than 10% of tumor cells (quantity); score
2 = moderate and complete staining of more than 10% of
tumor cells; score 3 = strong and complete staining of more
than 10% of tumor cells [20].
For ErbB2 immunoexpression, it was interpreted according
to the American Society of Clinical Oncology/College of
American Pathologists (ASCO/CAP) criteria for breast carci-
noma (score 0, no staining or membrane staining is observed
in <10% of the tumor cells; score 1+, faint/barely perceivableTable 2 Clinical characteristics of the studied cases of craniophary
ACP
Sex No. (
M 10 (56
F 8 (44%
Age 11.83
Clinical presentation No. (
Visual ﬁeld defects 8 (44%
Headache 5 (28%
Nausea/vomiting 4 (22%
Papilloedema 2 (11%
Diabetes insipidus 2 (11%
Cognitive dysfunction –
Ataxia/unsteadiness 1 (5%
Location No. (
Suprasellar/intrasellar 10 (55
Suprasellar 5 (28%
Intrasellar 3 (17%
Suprasellar/intrasellar in 10 cases, suprasellar in 5 cases, and intrasellar in
suprasellar in 2 cases.membrane staining is detected in >10% of the tumor cells,
and only part of the membrane is stained; score 2+, weak to
moderate complete membrane staining (tumor cells displayed
a circumferential staining of the entire tumor cell membrane)
is observed in >10% of the tumor cells; score 3+, strong com-
plete membrane staining is observed in >30% of the tumor
cells) [21].
Regarding p63, nuclear staining was scored as positive and
was scored as follows: (+1) <10% of nuclei were stained,
(+2) 20–50%, (+3) >50% [15].
Statistical analysis
Data were analyzed using SPSS version 12.0.0 for Windows
(SPSS Inc., Chicago, IL). Scale variables were presented as
the mean ± standard deviation (mean ± SD) or percentages
as appropriate. Fisher’s exact test was used to test the differ-
ence of immunohistochemical expression of each marker
between ACP and PCP. The P values were reported and the
signiﬁcance level was 0.05.Results
Clinical characteristic
The current study included 18 cases of APC and 7 cases of
APC. In ACP, 10 cases (56%) were males while the remaining
8 cases (44%) were females. The mean age of the patients was
11.83 ± 9.97 (range 2–42).
In PCP, 4 cases (57%) were male and 3 cases (43%) were
females. The mean age of the patients was 59.86 ± 6.69 (range
52–69). The difference in age between ACP and PCP is extre-
mely signiﬁcant (P value < 0.0001).
The main clinical manifestations in APC were visual ﬁeld
defects in 8 cases (44%), headache in 5 cases (28%), nau-
sea/vomiting in 4 cases (22%). Less frequent manifestations
were: papilledema in 2 cases (11%) and diabetes insipidus inngioma.
(18 cases) PCP (7 cases)
%) No. (%)
%) 4 (57%)
) 3 (43%)
± 9.97 59.86 ± 6.69
%) No. (%)
) 4 (57%)
) 1 (13%)
) –
) –
) –
3 (43%)
) –
%) No. (%)
%) 5 (71%)
) 2 (29%)
) –
3 cases. The location of PCP was suprasellar/intrasellar in 5 cases and
142 G.E. Esheba, A.A. Hassan2 cases (11%), and ataxia in one case (5%). Regarding APC,
visual ﬁeld defects was the most common clinical manifesta-
tion in 4 cases (57%), followed by cognitive dysfunction and
decreased consciousness in 3 cases (43%), and lastly headache
in one case (13%). Some patients were presented by more than
one clinical manifestation.
Regarding the location of the tumors; in ACP, it was:
suprasellar/intrasellar in 10 cases (55%), suprasellar in 5 cases
(28%), and intrasellar in 3 cases (17%). The location of PCP
was suprasellar/intrasellar in 5 cases (71%) and suprasellar
in 2 cases (29%). Detailed clinical characteristics of the
patients studied in this work are shown in Table 2.
Histopathological evaluation
All adamantinomatous craniopharyngiomas showed the pres-
ence of a complex epithelial pattern with epithelial cells dis-
posed in sheets, cords, nests, and anastomosing trabeculae
with peripherally palisading columnar epithelial cells with
darkly staining nuclei and little cytoplasm. Those areas merge
with loosely cohesive aggregates of squamous cells. WetFigure 1 (A) ACP exhibiting whorl-like cell cluster of epithelial cells
and nodules of ‘‘wet’’ keratin (arrow). (B) Loosely cohesive aggregates
ghost cells (arrow head) (H&E ·200). (D) Immunohistochemical sta
expression which was predominantly seen in compactly cohesive
immunostaining showing positive membranous expression in the neopl
(G) Strong diffuse nuclear p63 staining.keratin was identiﬁed in all cases. In 9 cases; cystic cavities
containing squamous debris were detected (Fig. 1A and B).
Calciﬁcation, ghost cells, and cholesterol clefts were
detected in 11 cases either singly or in combination (Fig. 1C).
Papillary CP was exclusively formed of a solid, papillary
growth pattern missing the wet keratin, cystic appearance
and regressive elements (Fig. 2A).
Immunohistochemical ﬁndings
Detailed immunohistochemical characteristics found in ACP
and PCP using b-catenin, EGFR, ErbB2, and p63 are summa-
rized in Table 3 and are shown in Figs. 1 and 2.
b-Catenin
A shift from membrane-bound to nuclear/cytoplasmic accu-
mulation of b-catenin was seen in all but one case (94%) of
the adamantinomatous CP, predominantly in the compactly
cohesive epithelial cells within the whorl-like arrays and occa-
sionally in palisaded cells, with 14 cases exhibited strongat different grades of differentiation, peripherally palisading cells
of squamous cells and cystic cavities. (C) Calciﬁcation (arrow) and
ining of b-catenin demonstrating strong nuclear and cytoplasmic
epithelial cells within the whorl-like arrays (·400). (E) EGFR
astic cells (·200). (F) +2 positive membranous staining for ErbB2.
Figure 2 (A) PCP shows well-differentiated squamous epithelium forming pseudopapillae lining loose connective tissue. Wet keratin is
absent (·200). (B) Exclusively membranous staining for b-catenin with no nuclear or cytoplasmic staining (·400). (C) Strong complete
membranous staining for EGFR (·400). (D) Focal p63 positivity (·200).
Table 3 Detailed immunohistochemical expression of b-catenin, EGFR, ErbB2 and p63 among ACP and PCP.
Adamantinomatous craniopharyngioma (18 cases) Papillary craniopharyngioma (7 cases) P-value
No. % Scoring of immunoreactivity No. % Scoring of immunoreactivity
0 +1 +2 +3 0 +1 +2 +3
b-catenin 17/18 94% 1 1 2 14 0/7 0 7 0 0 <0.0001*
EGFR 15/18 83% 3 3 8 4 5/7 71% 2 0 4 1 =0.7513
ErbB2 3/18 17% 15 0 2 1 0/7 0 7 0 0 00 =0.2798
p63 16/18 89% 2 0 0 16 6/7 86% 1 0 3 3 =0.2449
 P-value (the difference in positive immunoreactivity between ACP and PCP as calculated by Fisher’s exact test).
* Signiﬁcant value.
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erate staining, while the remaining case showed weak staining
intensity.
On the other hand, in PCP, b-catenin immunoreactivity
was exclusively present in the cellular membrane. The cyto-
plasm revealed only a focal weak expression, whereas
immunoreactivity was completely undetected in the nuclei
(Fig. 2B). The difference between b-catenin expression in
ACP and PCP was highly statistically signiﬁcant (P
value < 0.0001).
EGFR family
Regarding EGFR; 15 cases (83%) of APC and 5 cases (71%)
of PCP were positive. The difference between EGFR expres-
sion in ACP and PCP was statistically insigniﬁcant (P
value = 0.7513).The expression pattern of EGFR in APC was as follows: 4
cases had score 3 (Fig. 1E), 8 cases had score 2, while the
remaining 3 cases showed score 1.
In cases of PCP; one case exhibited score 3 (Fig. 1C), while
the remaining 4 cases had score 2.
On the other hand, only 3 cases of APC were positive for
ErbB2. One case had score 3, while the remaining 2 cases
had score 2 (Fig. 1F). All cases of PCP were either negative
or showed incomplete membranous staining. Similar to
EGFR, The difference of ErbB2 expression between ACP
and PCP was statistically insigniﬁcant (P value = 0.2798).
p63
16 out of 18 ACPs (89%) exhibited strong nuclear staining for
p63 (Fig. 2G), while 6 cases out of 7 PCPs (86%) were posi-
tive; half of the cases had score 3, while the remaining half
144 G.E. Esheba, A.A. Hassanhad score 2. Interestingly, the distribution of p63 staining was
diffuse in ACP, where it stained the nuclei of basal layer cells
and the whorl-like areas. However, in PCP, p63 positivity was
focal and mainly restricted to the lower third of the stratiﬁed
epithelial cells (Fig. 2D).
Discussion
Tumors arising from the sellar region are usually challenging
and sometimes pose a diagnostic problem in surgical pathol-
ogy and often only small tissue specimens are available for his-
tological diagnosis.
CPs are non-neuroepithelial epithelial tumors demonstrat-
ing a variable histological appearance and although they are
histologically benign, higher risk of recurrence has been
reported which requires extensive surgical treatment [1].
Twenty-ﬁve patients with CP were included in this study.
18 cases were ACP while the remaining 7 cases were PCP.
In ACP, 56% of cases were males while the remaining 44%
were females. The mean age of the patients was
11.83 ± 9.97. In PCP, 57% of cases were males and 43%
were females with a mean age of 59.86 ± 6.69. The difference
in age between ACP and PCP was extremely signiﬁcant (P
value < 0.0001).
In APC, the most common clinical manifestation was visual
ﬁeld defects in 44% of cases followed by headache in 28% of
cases and nausea/vomiting in 22% of cases. Regarding APC,
57% of cases were presented with visual ﬁeld defects, 43%
by cognitive dysfunction and decreased consciousness, and
one patient was presented with headache.
In ACP, the most common tumor location was suprasel-
lar/intrasellar in 55% of cases, 28% of cases were suprasellar,
and only 17% of cases were intrasellar. The location of PCP
was suprasellar/intrasellar in 5 cases (71%) and suprasellar
in 2 cases (29%).
The above results were in keeping with the previously pub-
lished data [2,3,7].
In the current study, ACP was characterized by complex
epithelial pattern with whorl-like arrays, peripherally palisad-
ing cells, keratin nodules, lobules, cystic spaces, and calciﬁca-
tions. On the other hand, the papillary variant was
predominantly solid and was composed of anastomosing cords
of squamous epithelium with a papillary conﬁguration pattern,
which lacked calciﬁcation or keratin nodule formation.
The pathogenesis of craniopharyngiomas is not fully under-
stood. Activating mutations of the gene encoding b-catenin
have been detected in the majority of ACP subtype but not
the papillary subtype. The b-catenin protein is encoded by
the CTNNB1 gene and is a key mediator of the canonical
WNT signaling pathway, which is essential in the control of
stem cell pluripotency, cellular differentiation, proliferation,
and migration. Mutation in the b-catenin gene has been
demonstrated to play an important role in tumor morphogen-
esis and epithelial differentiation of ACP but not in PCP
[12,13,15,16,22–24].
In the current work, we found quite different immunohisto-
chemical results for-b-catenin between the two subtypes of
craniopharyngioma. 94% cases of the adamantinomatous type
demonstrated strong cytoplasmic and nuclear accumulation.
On the other hand, the tumor cells in the papillary type showed
exclusively membranous staining.These results were in keeping with the previously published
data [12,15,22,23,25–27].
Moreover, the results of this study demonstrated speciﬁc b-
catenin expression patterns in ACP; in which nuclear accumu-
lation of b-catenin was restricted to cohesive cell clusters
within whorl-like areas and few in palisade cell. Similar results
have been previously reported [15,26].
Cani et al. observed mutations in the b-catenin gene in 64%
of ACP; they also found evidence of b-catenin gene over-
expression in 71% of the tumors with b-catenin mutations
and in 40% of the tumors without mutations. Surprisingly,
Cani et al. detected positive nuclear b-catenin staining pattern
regardless of the presence of b-catenin gene mutation.
Therefore, the authors concluded that WNT signaling activa-
tion plays an important role in the pathogenesis of ACP [14].
Recently, the EGFR cascade was demonstrated to also play
a role in Wnt signaling activation through a direct interaction
between EGFR and b-catenin [28].
In this work, EGFR was positive in 15 (83%) and 5 cases
(71%) of APC and PCP respectively.
These results were partially concordant with those of
Ho¨lsken et al., who found an activation of the EGFR signaling
pathway as determined by immunohistochemical staining in all
cases of ACP. However, the authors could not ﬁnd any muta-
tions or ampliﬁcations in the EGFR gene in their ACP cases.
They also suggested that EGFR signaling plays an important
role in cell migration and brain inﬁltration in cases of ACP.
Therefore, targeting the EGFR signaling pathway may be
promising in the treatment of this challenging tumor [17].
Despite the over-expression of ErbB2 in many human can-
cers and pituitary adenomas, its expression in ACP has not
been studied extensively. In the current work, only 3 cases
(17%) of APC and none of PCP exhibited positivity for
ErbB2. Nearly similar results were obtained by Zuhur et al.,
who found that only 10% of ACP had score 3+ for ErbB2.
However, they did not include the PCP in their study. Zuhur
et al. also observed that patients with 3+ ErbB2 staining
had large and more aggressive tumors [29].
Recently, p63 has been found to play a key role in epider-
mal proliferation and differentiation. Impaired p63 expression
has been recently discovered in squamous cell carcinomas aris-
ing in different organs, like the oral cavity, larynx, lung, and
uterine cervix [30].
In this study, we found strong positive nuclear staining for
p63 in 89% and 86% of ACPs and PCPs respectively; with
more focal distribution of p63 positive nuclei in PCPs cases,
where it stained mainly the nuclei of the basal cell layer.
The above results were partially concordant with those of
Cao et al., who found p63 over-expression in 45 out of 51
adamantinomatous craniopharyngiomas and 14 out of 15
squamous papillary craniopharyngiomas. However, in con-
trast to our data, the authors found uniform nuclear p63 stain-
ing in all cell types in the papillary craniopharyngiomas [15].
Conclusions
The present study clearly demonstrated that cytoplasm/nuclear
b-catenin accumulation is an exclusively characteristic hall-
mark of ACP, therefore, it can be used as a reliable marker
for the differentiation between ACP and PCP especially with
small surgical specimens. Moreover, the restricted nuclear b-
Immunohistochemical expression of b-catenin, EGFR, ErbB2, and p63 145catenin accumulation in the cohesive cell clusters within the
whorl-like areas supports that aberrant b-catenin expression
may play a role in the morphogenesis of ACP.
EGFR expression in many cases of ACP and PCP in this
study, justiﬁes targeting the EGFR signaling pathway as a
promising treatment of this challenging tumor.
p63 immunohistochemical over-expression was found in
both ACP and PCP variant but with different localizations.
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